Billing and coding for hematology-oncology groups, benign hematology clinics, hemophilia treatment centers and anticoagulation clinics.
Most hematology revenue sits on the drug line. An ESA claim with no hemoglobin value, IV iron billed per vial instead of per milligram, or a biologic coded as a plain infusion can lose more than the visit is worth. Our full-service medical billing team codes and follows up these claims inside your current EHR, with a BAA signed before we open a chart. Across 38 client practices, first-pass denial rate fell from 14.2% to 6.1% within 90 days of onboarding (Luxen client data).
On this page
Hematology billing services handle coding, claims, denials and AR for practices treating anemia, bleeding and clotting disorders and blood cancers. Most of the work is drug claims: HCPCS units, JW or JZ modifiers, ESA hemoglobin reporting and prior authorization. Medicare pays $177.02 nationally for an office bone marrow biopsy with aspiration (38222) in 2026.
Hematology claim mix depends on who the practice treats.
Service lines billed alongside: in-office infusion, CLIA lab work such as the CBC (85025), physician smear and marrow interpretation (85060, 85097), transfusion (36430) and apheresis (36514).
Hematology revenue leaks at the drug line, the marrow procedure and the small weekly codes. Our denials and AR recovery specialists work them oldest dollars first. Amounts: 2026 Medicare national non-facility rates.
| Scenario | Codes | What goes wrong | $ at stake per claim | Luxen audit finding |
|---|---|---|---|---|
| Same-bone aspiration and biopsy | 38220 + 38221 | NCCI requires 38222 | $157.65 recouped, or $177.02 if denied | Same-bone aspiration and biopsy were billed as 38220 plus 38221 on 6% of bone marrow claims |
| ESA claim with no lab value | J0881 or J0885 | Latest hemoglobin or hematocrit not reported | Full drug line | Hemoglobin or hematocrit values were missing on 12% of non-ESRD ESA claims, across 3,600 hematology claims |
| Rituximab coded as a therapeutic infusion | 96365 instead of 96413 | Monoclonal antibodies take chemotherapy administration codes | $66.13 on the first hour | Drug class checked before coding |
| IV iron billed per vial | J1439 (1 mg units) | A 750 mg dose goes out as 1 unit instead of 750 | Nearly the full drug line | IV iron units did not match the milligrams documented on 8% of iron infusion claims |
| Phone INR review with dose change | 93793 | Never charged | $11.69 per review | INR logs matched to charges weekly |
| Drug given without current approval | Drug HCPCS + 96413 | Authorization missing, expired or for another drug | Full drug and administration | Missing or invalid prior authorization caused 17% of denials |
Our certified medical coders code from the procedure note, lab log and infusion record.
| Code | What it covers | 2026 national non-facility |
|---|---|---|
| 99204 / 99214 | New / established patient visit, moderate | $177.36 / $135.61 |
| 99205 / 99215 | New / established patient visit, high | $236.81 / $192.39 |
| G2211 | Visit complexity add-on for ongoing care | $17.37 |
| 38220 | Diagnostic bone marrow aspiration | $167.67 |
| 38221 | Diagnostic bone marrow biopsy | $167.00 |
| 38222 | Biopsy and aspiration, same session | $177.02 |
| 85060 | Physician peripheral blood smear interpretation | $19.04 |
| 85097 | Bone marrow smear interpretation | $67.80 |
| 36430 | Transfusion of blood or blood components | $47.43 |
| 99195 | Therapeutic phlebotomy | $98.20 |
| 36514 | Therapeutic apheresis, plasma | $714.45 |
| 96413 / 96415 | Chemotherapy or biologic infusion, first hour / each added hour | $133.27 / $28.39 |
| 93793 | Warfarin management with INR review | $11.69 |
Total non-facility RVUs times the $33.4009 conversion factor ($33.5675 for qualifying APM participants), before locality adjustment. The 2026 efficiency adjustment cuts work RVUs 2.5% on procedure codes such as 38222, not on office visits.
G0364 was deleted at the end of 2017 and 38222 was created for 2018. Under the NCCI Policy Manual, an aspiration and biopsy from the same iliac bone is 38222. Report 38220 and 38221 together only when they come from different iliac bones or the sternum, or at separate encounters. The aspirate smear read is 85097 and the core biopsy read is 88305.
Medicare has paid G2211 since January 1, 2024 for ongoing care of a single serious or complex condition, such as sickle cell disease, hemophilia or chronic ITP. Since 2025 it pays on a modifier 25 visit only when the other same-day service is a preventive service, vaccine administration or an annual wellness visit.
Units come from the HCPCS descriptor, not the vial.
| Drug | HCPCS | Billing unit | Example dose and units |
|---|---|---|---|
| Ferric carboxymaltose | J1439 | 1 mg | 750 mg = 750 units |
| Iron sucrose | J1756 | 1 mg | 200 mg = 200 units |
| Sodium ferric gluconate | J2916 | 12.5 mg | 125 mg = 10 units |
| Iron dextran | J1750 | 50 mg | 100 mg = 2 units |
| Ferumoxytol, non-ESRD | Q0138 | 1 mg | 510 mg = 510 units |
| Ferric derisomaltose | J1437 | 10 mg | 1,000 mg = 100 units |
Administration is an infusion (96365, 96366) or IV push (96374), not 96372. NCD 110.10 covers iron sucrose and ferric gluconate only for hemodialysis patients on erythropoietin, so non-dialysis iron rests on documented deficiency and payer policy.
J0881 (darbepoetin, 1 mcg) and J0885 (epoetin alfa, 1,000 units) need EA, EB or EC. Every non-ESRD ESA claim reports the most recent hemoglobin or hematocrit: the MEA segment (R1 or R2) or item 19 on professional claims, value codes 48 or 49 on institutional claims.
Part B pays drugs at 106% of ASP; qualifying biosimilars get ASP plus 8% of the reference product ASP. JZ has been required since July 1, 2023 when nothing is discarded from a single-dose container.
Factor VIII (J7192) and factor IX (J7195) bill per international unit, factor VIIa (J7189) per microgram and emicizumab (J7170) per 0.5 mg, so a 105 mg emicizumab dose is 210 units. Medicare adds a blood clotting factor furnishing fee of $0.265 per unit for 2026 under Claims Processing Manual Chapter 17, section 80.4.1. On a 3,000 unit factor VIII dose that fee alone is $795.00.
A comprehensive hemophilia diagnostic treatment center receiving a federal grant under section 501(a)(2) is a 340B covered entity. Since January 1, 2025 every 340B covered entity reports modifier TB on separately payable Part B drugs; JG is retired.
NCD 190.11 covers home INR monitoring for patients with mechanical heart valves, chronic atrial fibrillation or venous thromboembolism who have been on warfarin for at least 3 months, with testing no more than once a week.
Therapeutic phlebotomy (99195) needs a treatment diagnosis such as D45 polycythemia vera, E83.110 hereditary hemochromatosis or D75.1 secondary polycythemia. Apheresis (36514) pays $714.45 in the office but $78.16 at the facility rate, so place of service drives what the practice is paid.
The rule: same iliac bone, same session, report 38222 only (NCCI Policy Manual, Chapter V). The cost: $157.65 recouped per case. Duplicate claim denials made up 9% of denials, mostly from resubmitting instead of correcting (Luxen claim audit).
The rule: anemia from treating myeloid cancers, cancer anemia unrelated to chemotherapy and doses past 8 weeks after the last chemotherapy are not covered (NCD 110.21). The cost: the full drug line. 19% of denied claims were never reworked or appealed (Luxen billing reviews).
The rule: 96372 is subcutaneous or intramuscular; IV iron is an infusion or IV push (Claims Processing Manual, Chapter 12). The cost: $51.78 per first hour against 96365. Coding and modifier errors caused 21% of denials (Luxen claim audit).
The rule: on a modifier 25 visit, Medicare pays G2211 only beside a preventive service, vaccine administration or annual wellness visit, not same-day chemotherapy administration (CMS MLN MM13473). The cost: $17.37 per visit, repaid on audit. The top three denial reasons accounted for 58% of denied dollars in the average practice (Luxen billing reviews).
The rule: Medicare adds a furnishing fee of $0.265 per unit in 2026 (CMS Transmittal 13379). The cost: $795.00 on a 3,000 unit dose. Underpayments against contracted rates appeared on 7.8% of paid claims (Luxen claim audit).
We run the revenue cycle from eligibility to zero balance inside the practice management system you already use. How full-service billing works.
Certified coders review charges against your documentation and payer rules before the claim goes out, so the denial is prevented rather than appealed. Medical coding.
Aged and denied claims are worked to resolution, then the upstream cause is fixed so the same claims stop coming back. Denials and AR recovery.
Benefits are verified and authorizations secured before the appointment, which is the cheapest place in the cycle to stop a denial. Eligibility and prior authorization.
Statements, balance questions and payment plans are handled by the same team that worked the claim. Patient billing.
Payer enrollment and re-credentialing are tracked through to approval, so a lapsed credential never quietly stops payment. Credentialing.
A HIPAA-trained front-office assistant working inside your EHR on calls, scheduling, intake and referrals, alongside the billing team. Medical virtual assistant.
Hematology-oncology groups mostly chart in oncology EHRs with regimen ordering and infusion documentation built in: Epic Beacon, OncoEMR, iKnowMed and Oracle Health. Benign hematology and anticoagulation clinics often run athenaOne, eClinicalWorks or NextGen, with INR logs and drug inventory in separate tools. We work inside the system you have, matching administration records to drug units, JW or JZ and lab values before a claim leaves. No migration. That matters: 38% had changed EHR or practice management system in the past five years, and of those, 71% said collections dipped for at least six months after the switch (Luxen Practice Manager Survey 2026).
2 weeks
from a signed BAA to our team working your claims
About 3 weeks
to the first recovered payments on aged AR
20+ years
combined billing and coding experience
Our highest-dollar claims were failing over small differences between ordered doses, administered units, and discarded drug amounts. Luxen added a claim-level audit and recovered $176,800 in previously delayed hematology revenue.
Revenue Cycle Director, hematology and infusion practice
Completed laboratory panels and physician visits were not always billed together when patients received same-day treatment. Luxen reconciled the daily schedule, found 219 missing services, and added $24,600 in monthly collections.
Practice Administrator, hematology clinic
Full engagements are written up in our dental practice case study and our ambulance billing case study.
The 2026 Part B deductible is $283; after it, the patient owes 20% on visits, administration and Part B drugs. On national rates, a new patient visit (99204) leaves $35.47 in coinsurance and a follow-up with G2211 ($152.98 together) leaves $30.60. Since April 1, 2023, some Part B drugs carry coinsurance on a lower, inflation-adjusted amount, so a flat 20% estimate can overcharge.
Our patient billing team handles those balances: plain-language statements plus text reminders raised patient collections 22% across 14 practices (Luxen client data).
Under 45 CFR 149.610, a self-pay patient scheduled 3 or more business days ahead gets an estimate within 1 business day; 10 or more days ahead, within 3 business days. A bill at least $400 above the estimate can go to patient-provider dispute resolution, so build estimates from the drug units the claim will carry.
Drug authorizations follow Medicare Advantage and commercial plan policy, and state law now sets some rules. Minnesota Statutes 62M.07 bars prior authorization for NCCN-consistent antineoplastic treatment other than medications, for plans issued or renewed from January 1, 2026. See how we handle medical billing in Minnesota. Alaska SB 133 takes effect January 1, 2027: 72 hours for a routine determination, 24 hours for an expedited one and extended authorizations for chronic conditions; see our Alaska medical billing page. Our eligibility and prior authorization team ties each drug approval to the regimen and date range.
3% to 6% of collections
Luxen's pricing generally falls between 3% and 6% of collections, depending on claim volume, specialty, payer mix, and how much of the revenue cycle your practice hands over.
Higher-volume practices usually land toward the lower end. Smaller or more complex practices land higher because there is more work per account. There is no setup fee and no exit fee, and the agreement runs month to month with 30 days notice.
A lower fee attached to weak billing is still expensive. The number that matters is what your collections do after you hire someone.
Luxen charges 3% to 6% of collections, set by drug volume, payer mix and authorization workload. No setup or exit fee.
| Service line | Monthly collections | Luxen at 3% | Luxen at 6% |
|---|---|---|---|
| Drugs: ESA, IV iron, factor, biologics | $78,000 | $2,340 | $4,680 |
| Visits and lab | $24,000 | $720 | $1,440 |
| Administration, marrow procedures, phlebotomy | $18,000 | $540 | $1,080 |
| Total | $120,000 | $3,600 | $7,200 |
| Cost | In-house | Luxen |
|---|---|---|
| Monthly | $9,480 (7.9% of collections) | $3,600 to $7,200 |
| Annual | $113,760 | $43,200 to $86,400 |
| When a biller leaves | Open biller roles took a median 67 days to fill | No gap in coverage |
| Terms | Salaries, benefits and software | Month to month, 30 days notice |
Fully loaded in-house billing cost 7.9% of collections for practices under $2M, across 96 practices that shared payroll data (Luxen billing reviews).
Ask the last one directly: 44% could not name the fee basis in their current billing contract, and 52% of practices that switched billing vendors cited missing denial reporting as the main reason (Luxen Practice Manager Survey 2026). You can also compare medical billing companies by state.
| Partner type | Drug and ESA claim checks | Start time | Cost basis |
|---|---|---|---|
| In-house biller | Depends on one person | Hiring and training | Payroll, benefits, software |
| Generalist billing company | Unit and lab value checks vary by biller | Weeks to months | Percent of collections |
| Specialty billing company | Usually covers infusion drugs | Weeks to months | Percent of collections or per claim |
| EHR vendor RCM | Tied to that EHR's rules | Requires their system | Percent plus software contract |
| Luxen | Certified coders check units, modifiers and lab values | About 2 weeks from signed BAA to working claims | 3% to 6% of collections, month to month |
A 30-minute look at your AR ageing, denial reasons and payer mix. You leave knowing what is recoverable, what we would work first and what it would cost.
We sign a business associate agreement before anyone touches your system. Your named team then works inside the practice management system and clearinghouse you already use. Nothing is migrated, and claims are being worked within two weeks of the signed BAA.
Aged and denied claims come first because that is revenue you have already earned. Most practices see the first recovered payments inside three weeks.
Once the backlog is moving, we take over the agreed part of the daily cycle: eligibility, coding review, submission, posting, denials and patient balances.
You know who owns your claims. The team works inside the practice management system and EHR you already run, with no migration.
Claims are coded by certified coders against your documentation and payer rules. Automation handles the repetitive checks so people spend their time on the claims that need judgment.
We sign a business associate agreement before accessing protected health information, and access is limited to the named people on your account.
We look at your AR ageing, volume, payer mix and denial profile first, then tell you what we believe is recoverable and what it would cost.
A billing company is a poor fit if you are not willing to share visibility into your billing, if the vendor uses a rotating pool of people who never learn your practice, or if it cannot explain why your claims are being denied. Be wary of anyone promising large collection increases before they have seen your AR ageing. The right partner makes your revenue cycle more visible, not less.
Medicare's 2026 national rate is $177.36 for a moderate new patient visit (99204) and $135.61 for a moderate follow-up (99214), plus $17.37 for G2211 when it applies. After the $283 Part B deductible, the patient owes 20%, about $35.47 for that new patient visit. Labs, infusions and drugs bill separately.
Each test needs an order with a supporting diagnosis, a CLIA certificate that covers the test and the QW modifier on waived tests. The CBC bills as 85025 and a physician's written smear interpretation as 85060, paid $19.04 nationally in 2026. Medicare claims must be filed within 12 months of the date of service under 42 CFR 424.44.
About 2 weeks from signed BAA to working claims. Median time from signed BAA to first claims worked was 9 business days, and first recovered payments arrived a median of 17 days after work began (Luxen client data). We start with open drug denials and the oldest AR, since Medicare timely filing ends 12 months after the date of service.
Yes. We work inside your existing EHR, practice management system and clearinghouse, so your infusion charting and drug ordering stay where they are. We reconcile administration records against HCPCS units, JW or JZ modifiers and ESA hemoglobin values before claims go out.
Not on Medicare when the visit carries modifier 25 for same-day drug administration such as 96413. Since 2025, CMS pays G2211 on a modifier 25 visit only beside a Part B preventive service, vaccine administration or annual wellness visit. A follow-up visit on a day with no procedure can still carry G2211.
Thirty minutes, no deck and no fee. We look at what is sitting past 90 days and where your denials cluster, and you leave knowing what is recoverable, what we would work first, and what it would cost.
Book a Billing Review%20(1).avif)
